Long-term and Quality of Survival in Patients Treated for Acute Lymphoblastic Leukemia During the Pediatric Age

Overview

Journal Hematol Rep

Publisher MDPI

Date 2021 Mar 22

PMID 33747412

Citations 3

Authors

Lara Devilli

Chiara Garonzi

Rita Balter

Elisa Bonetti

Matteo Chinello

Ada Zaccaron

Virginia Vitale

Massimilano De Bortoli

Giulia Caddeo

Valentina Baretta

Gloria Tridello

Simone Cesaro

Affiliations

Soon will be listed here.

Abstract

Long-term survival for acute lymphoblastic leukemia (ALL) in children improved over the last three decades up to 80-90% of affected patients. Consequently, the quality of life of survivors has become increasingly important. This study analyses the clinical features and outcome of 119 children with ALL, focusing on the quality of long-term survival in a subset of 22 patients over 18 years of age. Among this group, the 10-year event-free survival and overall survival were 83.1% (C.I. 74.0-89.2) and 88.4% (C.I. 80.9-93.1), respectively. Treatment related long-term medical complications were reported only in 2 patients (9.1%). Secondary school was completed successfully in 20 of 22 patients (89.9%). The remaining 2 patients were still attending at the time of the analysis. In conclusion, current treatment for ALL is well tolerated and does not compromise significantly the quality of life of survivors.

Citing Articles

Nutritional status at diagnosis and its relationship with survival and relapse in Mexican children with acute lymphoblastic leukemia: a retrospective study.

Guzman-Leon A, Gallegos-Castorena S, Romo-Rubio H, Casillas-Toral E, Lopez-Teros V, Stein K BMC Cancer. 2025; 25(1):325.

PMID: 39984931 PMC: 11846316. DOI: 10.1186/s12885-025-13729-5.

The impact of Indigenous American-like ancestry on risk of acute lymphoblastic leukemia in Hispanic/Latino children.

Langie J, Chan T, Yang W, Kang A, Morimoto L, Stram D medRxiv. 2025; .

PMID: 39867407 PMC: 11759616. DOI: 10.1101/2025.01.14.25320563.

Paediatric Acute Lymphoblastic Leukaemia: A Narrative Review of Current Knowledge and Advancements.

Elgazar S, Constantinou C Curr Oncol Rep. 2024; 26(12):1586-1599.

PMID: 39503990 DOI: 10.1007/s11912-024-01608-4.

Thymic stromal lymphopoietin signaling in B cells from progenitors to plasma cells.

Domeier P, Ziegler S J Leukoc Biol. 2024; 117(2).

PMID: 39373526 PMC: 11878999. DOI: 10.1093/jleuko/qiae216.

Nutritional interventions in children with acute lymphoblastic leukemia undergoing antineoplastic treatment: a systematic review.

Guzman-Leon A, Avila-Prado J, Bracamontes-Picos L, Haby M, Stein K, Astiazaran-Garcia H BMC Nutr. 2024; 10(1):89.

PMID: 38898513 PMC: 11186292. DOI: 10.1186/s40795-024-00892-4.

References

Byrne J, Fears T, Mills J, Zeltzer L, Sklar C, Nicholson H . Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004; 42(7):589-97. DOI: 10.1002/pbc.20033. View

Hunger S, Lu X, Devidas M, Camitta B, Gaynon P, Winick N . Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012; 30(14):1663-9. PMC: 3383113. DOI: 10.1200/JCO.2011.37.8018. View

Peckham V, Meadows A, Bartel N, Marrero O . Educational late effects in long-term survivors of childhood acute lymphocytic leukemia. Pediatrics. 1988; 81(1):127-33. View

Ness K, Armenian S, Kadan-Lottick N, Gurney J . Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health. Expert Rev Hematol. 2011; 4(2):185-97. PMC: 3125981. DOI: 10.1586/ehm.11.8. View

Kaste S, Pei D, Cheng C, Neel M, Bowman W, Ribeiro R . Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids. J Clin Oncol. 2015; 33(6):610-5. PMC: 4322260. DOI: 10.1200/JCO.2014.57.5480. View

Rizzari C, Lanvers-Kaminsky C, Valsecchi M, Ballerini A, Matteo C, Gerss J . Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica. 2019; 104(9):1812-1821. PMC: 6717578. DOI: 10.3324/haematol.2018.206433. View

Conter V, Arico M, Basso G, Biondi A, Barisone E, Messina C . Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2009; 24(2):255-64. DOI: 10.1038/leu.2009.250. View

Kawedia J, Kaste S, Pei D, Panetta J, Cai X, Cheng C . Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2010; 117(8):2340-7. PMC: 3062406. DOI: 10.1182/blood-2010-10-311969. View

Mostoufi-Moab S, Seidel K, Leisenring W, Armstrong G, Oeffinger K, Stovall M . Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2016; 34(27):3240-7. PMC: 5024546. DOI: 10.1200/JCO.2016.66.6545. View

10.

Viana M, Vilela M . Height deficit during and many years after treatment for acute lymphoblastic leukemia in children: a review. Pediatr Blood Cancer. 2007; 50(2 Suppl):509-16. DOI: 10.1002/pbc.21396. View

11.

Conter V, Bartram C, Valsecchi M, Schrauder A, Panzer-Grumayer R, Moricke A . Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010; 115(16):3206-14. DOI: 10.1182/blood-2009-10-248146. View

12.

Silverman L, Stevenson K, OBrien J, Asselin B, Barr R, Clavell L . Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2009; 24(2):320-34. PMC: 2820141. DOI: 10.1038/leu.2009.253. View

13.

Kunstreich M, Kummer S, Laws H, Borkhardt A, Kuhlen M . Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica. 2016; 101(11):1295-1305. PMC: 5394877. DOI: 10.3324/haematol.2016.147595. View

14.

Zerra P, Cochran T, Franco V, Lipshultz S . An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies. Expert Opin Pharmacother. 2013; 14(11):1497-513. DOI: 10.1517/14656566.2013.804911. View

15.

Jahnukainen K, Heikkinen R, Henriksson M, Cooper T, Puukko-Viertomies L, Makitie O . Semen quality and fertility in adult long-term survivors of childhood acute lymphoblastic leukemia. Fertil Steril. 2011; 96(4):837-42. DOI: 10.1016/j.fertnstert.2011.07.1147. View

16.

van Dalen E, Caron H, Kremer L . Prevention of anthracycline-induced cardiotoxicity in children: the evidence. Eur J Cancer. 2007; 43(7):1134-40. DOI: 10.1016/j.ejca.2007.01.040. View

17.

Krawczuk-Rybak M, Plonowski M, Leszczynska E, Latoch E, Sawicka-Zukowska M, Muszynska-Roslan K . The influence of different intensity of treatment on hormonal markers of gonadal function in acute lymphoblastic leukemia survivors. Hematol Oncol. 2019; 37(5):609-616. DOI: 10.1002/hon.2681. View

18.

Kizilocak H, Okcu F . Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors. Turk J Haematol. 2018; 36(1):1-11. PMC: 6373511. DOI: 10.4274/tjh.galenos.2018.2018.0150. View

19.

MOE P, Holen A, Glomstein A, Madsen B, Hellebostad M, Stokland T . Long-term survival and quality of life in patients treated with a national all protocol 15-20 years earlier: IDM/HDM and late effects?. Pediatr Hematol Oncol. 1997; 14(6):513-24. DOI: 10.3109/08880019709030908. View

20.

Niinimaki R, Harila-Saari A, Jartti A, Seuri R, Riikonen P, Paakko E . High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. J Clin Oncol. 2007; 25(12):1498-504. DOI: 10.1200/JCO.2006.06.2539. View